Baseline Characteristics from SEQUOIA-HCM to be Presented at HCMS Scientific Sessions on October 6, 2023
SOUTH SAN FRANCISCO, Calif., Oct. 02, 2023 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK), today announced upcoming presentations at the 2023 Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions on October 6, 2023, and at the Heart Failure Society of America (HFSA) Annual Scientific Meeting, taking place from October 6-9, 2023, both taking place in Cleveland, OH.
2023 HCMS Scientific Sessions
Poster Abstract Presentations
Title: Baseline Characteristics of Patients in SEQUOIA-HCM: A Phase 3 Trial of Aficamten in Obstructive Hypertrophic Cardiomyopathy
Presenter: Martin S. Maron, M.D., Director of the Hypertrophic Cardiomyopathy Center at Lahey Hospital and Medical Center
Date: October 6, 2023
Session Title: Poster Abstract Presentations
Session Time: 1:00 – 1:45 PM ET
Location: Hilton Cleveland Downtown
HFSA Annual Scientific Meeting
Poster Presentations
Title: Characteristics and Procedural Complications of Septal Myectomy for Obstructive Hypertrophic Cardiomyopathy in the United States
Presenter: Ahmed Altibi, M.D., MPH, Cardiology Fellow, Division of Cardiovascular Medicine, Oregon Health & Science University
Date: October 7, 2023
Session Title: ePoster Viewing Sessions – ePoster Viewing Session II
Poster Number: 139
Session Time: 8:00 – 9:00 AM ET
Presentation Time: 8:30 – 9:00 AM ET
Location: Exhibit Hall‚ ePoster Hub
Title: Symptoms and Complications Significantly Increase the Logistic and Economic Burden of Obstructive Hypertrophic Cardiomyopathy – Results from Medical and Pharmacy Claims Data
Presenter: Meiling Chen, M.D., Cardiology Research Fellow, HCM Center of Excellence, University of California, San Francisco Medical Center
Date: October 7, 2023
Session Title: ePoster Viewing Sessions – ePoster Viewing Session III
Poster Number: 163
Session Time: 1:00 – 2:30 PM ET
Presentation Time: 1:00 – 1:30 PM ET
Location: Exhibit Hall‚ ePoster Hub
Title: Cardiovascular Hospitalizations Post Septal Myectomy for Obstructive Hypertrophic Cardiomyopathy: A 3-year Analysis of 5,101 Patients
Presenter: Ahmed Altibi, M.D., MPH, Cardiology Fellow, Division of Cardiovascular Medicine, Oregon Health & Science University
Date: October 7, 2023
Session Title: ePoster Viewing Sessions – ePoster Viewing Session III
Poster Number: 191
Session Time: 1:00 – 2:30 PM ET
Presentation Time: 1:30 – 2:00 PM ET
Location: Exhibit Hall‚ ePoster Hub
Title: A Phase 3, Multicenter, Randomized, Double-blind Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults with Symptomatic Non-obstructive Hypertrophic Cardiomyopathy
Presenter: Ahmad Masri, M.D., MS, Director of the Hypertrophic Cardiomyopathy Center at Oregon Health & Science University
Date: October 7, 2023
Session Title: ePoster Viewing Sessions – ePoster Viewing Session III
Session Time: 1:00 – 2:30 PM ET
Poster Number: CTC-005
Presentation Time: 2:00 – 2:30 PM ET
Location: Exhibit Hall‚ ePoster Hub
Title: A Phase 3 Randomized Controlled Trial Comparing Aficamten vs Metoprolol in Patients with Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction
Presenter: Michael A. Fifer, MD, Director of Hypertrophic Cardiomyopathy Program at Massachusetts General Hospital Heart Center
Date: October 7, 2023
Session Title: ePoster Viewing Sessions – ePoster Viewing Session IV
Poster Number: CTC-006
Session Time: 4:45 – 5:45 PM ET
Presentation Time: 4:45 – 5:15 PM ET
Location: Exhibit Hall‚ ePoster Hub
About Cytokinetics
Cytokinetics is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact myocardial muscle function and contractility. Aficamten is a next-in-class cardiac myosin inhibitor, currently the subject of three Phase 3 clinical trials: SEQUOIA-HCM, evaluating aficamten in patients with obstructive hypertrophic cardiomyopathy (HCM), MAPLE-HCM, evaluating aficamten as monotherapy compared to metoprolol as monotherapy in patients with obstructive HCM and ACACIA-HCM, evaluating aficamten in patients with non-obstructive HCM. Cytokinetics is also developing omecamtiv mecarbil, a cardiac muscle activator in patients with heart failure. Additionally, Cytokinetics is developing CK-136, a cardiac troponin activator for the potential treatment HFrEF and other types of heart failure, such as right ventricular failure, resulting from impaired cardiac contractility, and CK-586, a cardiac myosin inhibitor with a mechanism of action distinct from aficamten for the potential treatment of HFpEF. In 2023, Cytokinetics is celebrating its 25-year history of pioneering innovation in muscle biology and related pharmacology focused to diseases of muscle dysfunction and conditions of muscle weakness.
For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on Twitter, LinkedIn, Facebook and YouTube.
Forward-Looking Statements
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act’s Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics’ and its partners’ research and development activities of Cytokinetics’ product candidates. Such statements are based on management’s current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics’ business outlined in Cytokinetics’ filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and Cytokinetics’ actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
CYTOKINETICS® and the CYTOKINETICS and C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.
Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Corporate Communications, Investor Relations
(415) 290-7757
